Microplastics and dementia: we are optimising outdated biological environments
There’s a version of the longevity conversation I find genuinely interesting, and a version I find beside the point. The distraction is the “living until 150” narrative. What is genuinely interesting is about what the last thirty years of life could look like: whether you can walk without pain, think clearly, remember and engage with your loved ones, and move through the world with agency. All these processes are positive feedback loops to longer lives, anyways.
The longevity market is predicted to reach over $300 billion by 2030, and I find too little capital allocated to tissue-specific deteriorations that determine quality of life. From my medical perspective, four matter most, and cause the most pain in old age:
Brain tissue deterioration
Cartilage
Bone density
Cardiovascular stiffening
Here’s where the tech stands in each domain, and how I see them evolving. In this article I address the first and most pressing one, brain tissue.
Brain tissue is where stakes are highest and the situation most urgent. Alzheimer’s alone consumed $345 billion in U.S. health expenditures in 2024. Companies like YouthBio Therapeutics are pursuing partial cellular reprogramming with Yamanaka factors with promising outcomes supported by early mouse data. The insight here is that ageing is mostly epigenetic rather than genetic: DNA is mostly intact, while ageing is caused by DNA being read differently as methylation patterns drift.
But here is what that entire pipeline is not accounting for, and which may become a limiting factor for companies in the field: microplastics are accumulating in brain tissue at increasing concentrations. A 2024 Nature Medicine study confirmed levels significantly higher than in liver or kidney, and higher still in brains of people who died with dementia. Whether cause or consequence, the correlation is too striking for any serious longevity company to ignore. In any case, the microplastic-associated environment (alongside drivers like vascular dysfunction, metabolic disease, and protein aggregation) of inflammatory signaling, mitochondrial stress, and oxidative load may constitute a continuous re-aging pressure that the reprogrammed cell now has to resist.
The biological substrate that these reprogramming therapies are trying to rejuvenate is being continuously exposed to this environment. A neuron that has been epigenetically reset still contains the same plastic burden. And if microplastics are contributing to accelerated epigenetic ageing through chronic inflammation, mitochondrial damage, and accumulation, then reprogramming without addressing this burden risks is like running in place: the therapy isn’t optimised for the new environment our brains are becoming.
Removing microplastics in the brain directly isn’t currently feasible. Nanobots face fundamental problems like:
Surface functionalization: dozens of polymer chemistries make a single type of plastic to bind to difficult
Scale mismatch: nanobots that can cross the blood brain barrier would likely be too small to transport microplastics, which are substantially larger
Blood brain barrier selectivity, that makes direct outward transport difficult
The most viable route today for improving clearance of waste products in the brain already exists: glymphatic clearance, the brain’s endogenous waste clearance system.
Tech in brain health should focus on ways to improve glymphatic clearance alongside cellular reprogramming: companies need to adapt to the current state of public health instead of staying in theory / academia for too long.
The winner in the field will likely simultaneously develop cellular reprogramming with improved environmental and clearance dynamics. The one that develops cellular reprogramming in isolation, while ignoring the new environment our brains have become, may see its clinical outcomes plateau in ways it won’t immediately understand.
The company that meaningfully improves clearance of persistent stressors could become a pillar for longevity infrastructure: without it, other longevity companies won’t reach their full potential. If P is the probability that a cellular reprogramming therapy works, and Q is the probability of sufficiently reducing environmental burden, then the probability of success of the epigenetics company isn’t P, but P times Q. Right now the field is largely pricing in P and underweighting Q.
I predict significant capital flowing toward this class of problems within the decade: some interesting paths being CSF (cerebrospinal fluid) production manipulation for higher clearance, AQP4 polarisation modulating drugs, and even straight-forward prevention (D2C) if the public is pushed to enough urgency about the microplastic problem (lifestyle-focused protocols). The one wildcard: if cellular reprogramming proves to be robust enough to raise neuronal resilience against environmental stressors, it partially reframes the problem. In any case, though: it still doesn’t evacuate particles. The physical burden remains. Which is why clearance and reprogramming are within the same bet.
As long as governments don’t aggressively ban plastics, high-risk pesticides, and known chemical disruptors (and they show little sign of doing so), this is a problem longevity companies may need to address downstream: upstream is out of the private sector’s control.
Microplastics are just one example of counterproductive contamination. Before we engineer cells to perform better, we need to ensure the environment they operate in isn’t continuously degrading them. Genetic therapies may reset the system, but their full benefit will only emerge in biological environments that are not continuously pushing cells back toward dysfunction.
